Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cancer immunotherapy: exploiting neoepitopes.

Cell research - 1 Aug 2015

Platten Michael, Offringa Rienk

Abstract excerpt

The efficacy of cancer vaccines has long been hampered by insufficient definition of tumor-specific antigens. A recent study by Kreiter et al. published in Nature has provided a blueprint for a patient-tailored approach to develop individualized RNA vaccines.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Epitopes, T-Lymphocyte
Share to Histocompatibility Antigens Class II
Share to Immunotherapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Melanoma, Experimental

Share to Mutation

Source

Open in PubMed Open full text

Identifiers

PMID: 26032267
DOI: 10.1038/cr.2015.66
PMCID: PMC4528051

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cancer immunotherapy: exploiting neoepitopes.PMID 26032267Read ↗

Neoepitopes as Cancer Immunotherapy Targets: Key Challenges and OpportunitiesSemantic proximity Read ↗

Cancer immunotherapy: broadening the scope of targetable tumours.Semantic proximity Read ↗

Cancer Vaccines: Recent Insights and Future DirectionsSemantic proximity Read ↗

Can we predict mutant neoepitopes in human cancers for patient-specific vaccine therapy?Semantic proximity Read ↗

Cryptic but critical: non-canonical antigens in cancer immunotherapy.Semantic proximity Read ↗

Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer.Semantic proximity Read ↗

Molecular targets and strategies in the development of nucleic acid cancer vaccines: from shared to personalized antigensSemantic proximity Read ↗

Mutanome Engineered RNA Immunotherapy (MERIT).Semantic proximity Read ↗

Boosting Antitumor Immunity with an Expanded Neoepitope Landscape.Semantic proximity Read ↗

Employing RNA editing to engineer personalized tumor-specific neoantigens (editopes)Semantic proximity Read ↗

Tumor Antigens beyond the Human Exome.Semantic proximity Read ↗

Emerging Strategies in TCR-Engineered T CellsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.